Pro 2014-012 (Announcement of Jianfeng Group on the Sale of Tianjin Jianfeng Equity)
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2014-012
浙江尖峰集团股份有限公司
关于出售子公司股权的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l交易简要内容:本公司的控股子公司浙江尖峰药业有限公司持有天津市尖峰天然产物研究开发有限公司54.5%的股权,本次尖峰药业与法国Diana Naturals SAS公司签订了《有约束力的框架协议》,拟以6322万元(人民币)的价格出售该股权。
l本次交易不构成关联交易
l本次交易不构成重大资产重组
l交易实施不存在重大法律障碍
l本次签订的为有约束力的框架协议,还需经双方进一步谈判和协商,在达成正式股权转让协议并经相关政府部门批准后实施。
一、交易概述
(一)本公司的控股子公司浙江尖峰药业有限公司(以下简称“尖峰药业”)持有天津市尖峰天然产物研究开发有限公司(以下简称“尖峰天然产物”)54.5%的股权。2014年5月28日,尖峰药业与法国Diana Naturals SAS(以下简称“戴安娜天然”)签订了《有约束力的框架协议》-受制于先决条件和合同(以下简称“框架协议”),拟以6322万元(人民币)的价格向戴安娜天然或其指定的买方出售该股权。本次交易不构成关联交易。
(二)董事会审议情况
本公司于2014年5月28日以通信方式召开了八届十六次董事会,公司八名董事全部参加了会议,经审议与表决,董事会以8票同意、0票反对、0票弃权审议通过了该股权转让事宜。
(三)根据公司章程的规定,该股权转让事宜不需报股东大会审议。本次签订的仅为有约束力的框架性协议,后续双方将进一步谈判和协商,在达成正式股权转让协议并经相关政府部门批准后实施。
二、交易对方情况介绍
(一)基本情况
1、企业名称:Diana Naturals SAS
2、注册地:5 rue de la Gare, BP 15, 35560 Antrain, 法国
3、法定代表人:Jean-Yves Parisot
4、注册资本:9,511,920欧元
5、企业性质:简单股份制公司
6、主要办公地点:5 rue de la Gare, BP 15, 35560 Antrain,法国
7、主营业务:戴安娜天然主要从事生产和销售源自天然原料的功能性食品解决方案。
8、控制人:戴安娜天然的控制人为 Diana SAS。
(二)交易对方发展状况
戴安娜天然是戴安娜集团食品部的组成部分,戴安娜集团成立于1990年,是一家针对食品、宠物食品、保健品、水产养殖及化妆品产业提供天然感官与功能性解决方案的法国生物科学公司,主要业务划分为三大领域:食品、宠物食品和健康营养。
戴安娜天然2013年的营业收入为1.33亿欧元,2013年末的资产总额为1.67亿欧元、资产净额为2千3百万欧元,财务数据未经审计。
三、交易标的基本情况
1、交易标的:天津市尖峰天然产物研究开发有限公司的54.5%的股权;
2、注册资本:1000 万元(人民币);尖峰药业占54.5%股权;
3、设立时间:1999年12月;
4、注册地点:天津市经济开发区12大街南黄海路西;
5、主营业务:研究、生产和销售天然植物提取产品;
6、尖峰天然产物的经营和财务情况(2013年数据经具有从事证券、期货业务资格的天健会计师事务所审计,2014年一季度数据未经审计):
|
项目(万元人民币) |
2013年末 |
2014年一季度末 |
|
资产总额 |
8680.41 |
9101.96 |
|
负债总额 |
4493.24 |
4757.73 |
|
净资产 |
4187.17 |
4344.23 |
|
|
2013年 |
2014年一季度 |
|
营业收入 |
10054.52 |
2417.36 |
|
利润总额 |
866.98 |
184.77 |
|
净利润 |
763.41 |
157.06 |
7、资产权属:本次出售的股权无设定担保、抵押及其它任何转让的情况,无涉及该资产的诉讼、仲裁或司法强制以及其它重大争议事项。
四、协议的主要条款
“DIANA” 或“买方”:Diana Naturals SAS或任何其他Diana Naturals SAS或戴安娜集团指定取代其签署股权转让协议的关联公司
“尖峰药业”或“卖方”:浙江尖峰药业有限公司
2014年5月28日,双方签订了一份有约束力的框架协议,协议的主要内容如下:
(一)交易范围
买方确认其有意直接或通过任何其指定的实体收购尖峰天然产物100%的股权,其中向卖方收购其持有的54.5%的股权。
(二)交易对价和估值基础
买方为收购卖方所持有的尖峰天然产物54.5%股权提出交易对价为人民币陆仟叁佰贰拾贰万元(RMB 6322万元)的有约束力的要约, 而该要约为卖方所接受,前提是本交易项下的尖峰天然产物100%股权均出售给买方,并且此要约受制于下文所列的签署前预设条件和股权转让协议的条件。交易对价为各方基于对尖峰天然产物截至2013年12月31日(“基准日”)的财务报表以及全面尽职调查的结果,经双方谈判商定的公司整体价值而确定。
(三)卖方在股权转让协议签署前保证完成的事项
1、卖方同意使买方得以对其分别大约10个关键客户和供应商进行访谈, 以验证与上述合作伙伴的业务的真实性和可持续性;
2、100%尖峰天然产物的股东(“所有卖方”)都应签署与本框架协议的条款和条件实质相同的另一份框架协议;
3、尖峰天然产物所有个人股东签署文件授权尖峰药业董事长代表所有个人股东协商股权转让协议,但所有个人股东均应受买方和蒋先生协商并达成一致的股权转让协议的约束,并分别签署该股权转让协议;
4、在本框架协议签署后,卖方将允许买方查阅尖峰天然产物2013年的最终财务报表;
5、在签署股权转让协议之前, 在不违背中国法律,并在中国政府允许的情况下,将由一家具有资质的天津环境评估公司进行若干有关地下水和土壤污染的标准检测(费用由买方承担)。 评估公司的选择将由各方同意确认;
6、尖峰天然产物取得果蔬粉车间的房地产权证;
7、向有关政府部门取得正式的书面函同意二期土地(定义见下文)的建设延迟至2015年12月;
8、买方将审阅尖峰天然产物准备向有关部门提交的更新高新技术企业(“高新企业”)证书的申请文件;
9、尖峰天然产物总经理承诺在其所得报酬不低于目前水平的前提下,继续在尖峰天然产物任职至少24个月(自交易的交割日起计算);
10、尖峰天然产物现任副董事长在和买方就报酬达成协议的前提下签署顾问合同
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11